Highly active antiretroviral therapy and left ventricular diastolic function in children with human immunodeficiency virus infection
Abstract
Background In the past, cardiovascular involvement did not seem to be a common complication of HIV, but in recent years it has been described more frequently. With the advent of highly active antiretroviral therapy (HAART), the symptoms of cardiac disease has changed, as the number of HIV-infected patients with abnormal diastolic parameters has increased significantly, often presenting as symptomatic rather than asymptomatic.
Objective To analyze for a possible correlation between HAART duration and left ventricular diastolic function in HIV-infected children.
Methods This cross-sectional study was conducted from December 2016 to December 2017 at the Cardiology and Allergy-Immunology Division/Department of Child Health, Universitas Udayana Medical School/Sanglah Hospital, Denpasar, Bali. Subjects with HAART were collected using a consecutive sampling method. The following data were recorded for each subject: age, sex, current stage of HIV, CD4+ level, as well as HAART regimen and duration of use. Transthoracic echocardiography was performed for tissue doppler imaging (TDI) of diastolic function. Spearman’s test was used to analyze the strength of correlation based on normality test results.
Results This study involved 53 subjects, 21 of whom had impaired diastolic function. There was no correlation between HAART duration and diastolic function in children with HIV infection (r= -0.03; P=0.82).
Conclusion Diastolic dysfunction is found in children under HAART treatment, but there is no correlation between HAART treatment duration and diastolic dysfunction.
References
2. Remick J, Georgiopoulou V, Marti C, Ofotokun I, Kalogeropoulos A, Lewis W, Butler J. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation. 2014;129:1781-9.
3. Bhardwaj A, Parikh R, Daoko J, Singh L, Shamoon FE, Slim J. Cardiovascular manifestation of HIV: review. J Antivir Antiretrovir. 2012;1:11-16.
4. Ntsekhe M, Mayosi BM. Cardiac manifestation of HIV infection; an African perspective. Nat Clin Pract Cardiovasc Med. 2009;6:120-7.
5. Fisher SD, Starc TJ, Guerra V, Williams PL, Wilkinson JD, Lipshultz SE. Declining incidence of systolic left ventricular dysfunction in human immunodeficiency virus-infected individuals treated with highly active antiretroviral therapy. Am J Cardiol. 2016;117:1194-5.
6. Chelo D, Wawo E, Siaha V, Anakeu A, Aleba Ndongo F, Koki Ndombo PO, et al. Cardiac anomalies in a group of HIV-infected children in a pediatric hospital: an echocardiographic study in Yaounde, Cameroon. Cardiovasc Diagn Ther. 2015;5:444-53.
7. Cade WT, Waggoner AD, Hubert S, Krauss MJ, Singh GK, Overton ET. Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero. AIDS. 2012;26:2053-8.
8. Kadappu KK, Thomas L. Tissue Doppler imaging in echocardiography: value and limitations. Heart Lung Circ. 2015;24:224-33.
9. Ho CY. Echocardiographic assessment of diastolic function. In: Solomon SD, editor. Contemporary cardiology: essential echocardiography: a practical handbook. Totowa: Humana Press; 2002. p. 119-31.
10. Kementerian Kesehatan Republik Indonesia. Pedoman peenerapan terapi HIV pada anak. Jakarta: Kemenkes RI; 2014. p. 50-58.
11. Achappa B, Madi D, Bhaskaran U, Ramapuram JT, Rao S, Mahalingam S. Adherence to antiretroviral therapy among people living with HIV. N Am J Med Sci. 2013;5:220-3.
12. Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008;22:89-95.
13. Lipshultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev Anti Infect Ther. 2012;10:661–74.
14. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77:158-73.
15. Lipshultz SE, Orav J, Sanders SP, Hale AR, McIntosh, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. New Engl J Med. 1992;327:1260-5.
16. Kuswiyanto RB, Djer M, Akib AAP, Sastroasmoro S. Ventricular function and dimensions in children with human immunodeficiency virus infection. Paediatr Indo. 2011;51:149-56.
17. Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52:378-86.
18. Lewis W, Grupp IL, Grupp G, Hoit B, Morris R, Samarel AM, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest. 2000;80:187-97.
19. Luo L, Ye Y, Liu Z, Zuo L, Li Y, Han Y, et al. Assessment of diastolic cardiac dysfunction in HIV–infected people without cardiovascular symptoms in China. Int J STD AIDS. 2010;21:814-8.
20. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee S, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr. 2002;30:306-10.
Copyright (c) 2019 Ni Made Ayu Agustini, Eka Gunawijaya, Ni Putu Venny Kartika Yantie, Ketut Dewi Kumara Wati, Komang Ayu Witarini, Hendra Santoso
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2019-06-19
Published 2019-06-19